Homepage: http://www.vbivaccines.com

Management: http://www.vbivaccines.com/about/management-team/

About: http://www.vbivaccines.com/about/

Events/Presentation: http://www.vbivaccines.com/investors/events-presentations/

Technlogy: http://www.vbivaccines.com/technology/

Pipeline: http://www.vbivaccines.com/programs/

Investors: http://www.vbivaccines.com/about/

News: http://www.vbivaccines.com/wire/

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vacis approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel..